巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-12-26
2022-01-19
2023-02-23
2023-02-24
2021-12-27
2021-11-27
2021-10-21
2022-01-16
2021-09-17
2021-12-03
2021-12-17
2023-03-11
